艾愈胶囊联合化疗治疗晚期胃癌的有效性及安全性观察

Clinical Observation of the Efficacy and Safety of Aiyu Capsule Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer

目的:探讨艾愈胶囊辅助化疗治疗胃癌的临床疗效及其安全性。方法:选取湖南省肿瘤医院在2013年4月至2014年5月收治的胃癌患者84例为研究对象,随机分为观察组与对照组。对照组给予单纯化疗治疗,观察组在对照组的基础上给予艾愈胶囊治疗。对两组近期疗效及发生毒副反应情况进行对比。结果:观察组的疾病控制率与总有效率分别是90.48%、45.24%,对照组疾病控制率与总有效率分别为61.90%、27.50%,观察组显著升高,差异有统计学意义(P<0.05);与对照组相比,观察组患者血红蛋白减少、恶心呕吐的发生率显著降低,差异有统计学意义(P<0.05)。结论:艾愈胶囊辅助化疗治疗胃癌能够显著提高疗效,减轻白细胞减少症。

Objective To explore the clinical efficacy and safety of adjuvant chemotherapy in the treatment of gastric cancer. Method 84 patients with gastric cancer from April 2013 to May 2014 were randomly divided into observation group and control group. The control group was treated with chemotherapy alone, and the observation group was treated with the therapy of the capsule on the basis of the control group. The short-term efficacy and adverse reactions of the two groups were compared. Result The control rate and total effective rate were 90.48 % and 45.24 % respectively, and the control group was 61.90 % and 27.50 % respectively, the observation group was significantly higher than the control group, the difference was statistically significant（P0.05）, and the incidence of hemoglobin in the observation group was significantly lower than that in the control group（P0.05）. Conclusion Adjuvant chemotherapy for gastric cancer can significantly improve the efficacy, reduce the number of white blood cells, it is worthy of clinical promotion.